| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Basic Study |
| Article Title |
Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Peng Wang, Dan Shi, Duo Yun, Jun Hu, Jie-Fu Wang, Jia Liu, Yan-Peng Yang, Ming-Rui Li, Jun-Feng Wang and Da-Lu Kong |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Tianjin Key Medical Discipline (Specialty) Construction Project |
TJYXZDXK-009A |
| Tianjin Medical University Cancer Hospital National Natural Science Foundation Cultivation Program |
220108 |
| National Natural Science Foundation of China |
82373134 |
| Science and Technology Development Fund of Tianjin Education Commission for Higher Education |
2022KJ228 |
| Chinese Anti-Cancer Association-Heng Rui Anti-angiogenesis Targeted Tumor Research Fund |
2021001045 |
| Scientific Research Translational Foundation of Wenzhou Safety (Emergency) Institute of Tianjin University |
TJUWYY2022025 |
|
| Corresponding Author |
Da-Lu Kong, BMed, Chief Physician, Director, Doctor, Department of Colorectal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Hexi District, Tianjin 300060, China. kongdalu2021@126.com |
| Key Words |
Esophageal squamous cell carcinoma; JOSD2; Ubiquitination; Biomarker; Targeted therapy; Drug resistance |
| Core Tip |
JOSD2, a deubiquitinating enzyme, is a key player in the aggressive pathogenesis of esophageal squamous cell carcinoma (ESCC). Elevated JOSD2 expression in ESCC tissues is associated with poor prognosis. Functional analyses, including in vivo xenograft assays, highlight JOSD2's role in promoting tumor proliferation and drug resistance. Mechanistically, JOSD2 activates the MAPK/ERK and PI3K/AKT signaling pathways. Mass spectrometry identified key interacting proteins, including USP47, IGKV2D-29, HSP90AB1, and PRMT5. This study underscores the potential role of JOSD2 as a therapeutic target in ESCC. |
| Publish Date |
2024-02-05 12:08 |
| Citation |
Wang WP, Shi D, Yun D, Hu J, Wang JF, Liu J, Yang YP, Li MR, Wang JF, Kong DL. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma. World J Gastroenterol 2024; 30(6): 565-578 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i6/565.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i6.565 |
